Cone Biopharma (CNTB, Financial) experienced a significant stock drop of 5.47%, currently trading at $1.21 per share. The trading volume reached 777 shares, with no notable turnover rate.
Financial results show the company achieved revenue of $24.12 million, a net profit of $7.65 million, and earnings per share of $0.14. The company's gross profit stood at $23.64 million, with a negative P/E ratio of -3.26.
In terms of analyst ratings, one brokerage firm rates the stock as a buy, with no hold or sell recommendations. The biotech sector, where Cone Biopharma operates, saw an overall decline of 0.30%.
Within the industry, stocks like Apollomics Inc, Inhibikase Therapeutics, Inc., and Kezar Life Sciences, Inc. have shown notable rises. Additionally, Windtree Therapeutics, Inc., Aditxt, Inc., and Inhibikase Therapeutics, Inc. displayed active trading with high turnover rates of 705.11%, 443.14%, and 221.19%, respectively. Stocks with large price swings include Psyence Biomedical Ltd, Inhibikase Therapeutics, Inc., and Cue Biopharma, Inc.
Cone Biopharma is a clinical-stage company focusing on developing next-generation immunotherapies for severe autoimmune and inflammatory diseases, leveraging its expertise in T-cell regulation biology. Its development pipeline includes CBP-201, CBP-307, and CBP-174.
